Cartesian Therapeutics, Inc. — Director's Dealing 2023

Nov 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2023-11-13

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-15	Series A Convertible Preferred Stock	A	24785.081	$403.4685	Acquired	24785.081	Indirect
2023-11-15	Series A Convertible Preferred Stock	A	123925.407	$403.4685	Acquired	123925.407	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-13	Stock Option (Right to Buy)	$17.47	D	6410	Disposed	2027-06-15	Common Stock (6410)	Direct
2023-11-13	Stock Option (Right to Buy)	$12.75	D	10000	Disposed	2028-06-14	Common Stock (10000)	Direct
2023-11-13	Stock Option (Right to Buy)	$2.10	D	10000	Disposed	2029-06-13	Common Stock (10000)	Direct
2023-11-13	Stock Option (Right to Buy)	$3	D	20000	Disposed	2030-06-18	Common Stock (20000)	Direct
2023-11-13	Stock Option (Right to Buy)	$4.01	D	40000	Disposed	2031-03-29	Common Stock (40000)	Direct
2023-11-13	Stock Option (Right to Buy)	$3.31	D	40000	Disposed	2032-01-02	Common Stock (40000)	Direct
2023-11-13	Stock Option (Right to Buy)	$1.13	D	75000	Disposed	2033-01-01	Common Stock (75000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	86418	Indirect
Common Stock	7293625	Direct
Common Stock	29868490	Indirect

Footnotes

F1: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

F2: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.

F3: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.

F4: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger.

F5: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.

F6: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.

F7: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.

F8: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.